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Abstract
Cancers are driven by a population of cells with the stem cell properties of self-renewal and unlimited growth. As a
subpopulation within the tumor mass, these cells are believed to constitute a tumor cell reservoir. Pathways controlling the
renewal of normal stem cells are deregulated in cancer. The polycomb group gene Bmi1, which is required for neural stem
cell self-renewal and also controls anti-oxidant defense in neurons, is upregulated in several cancers, including
medulloblastoma. We have found that Bmi1 is consistently and highly expressed in GBM. Downregulation of Bmi1 by
shRNAs induced a differentiation phenotype and reduced expression of the stem cell markers Sox2 and Nestin. Interestingly,
expression of glycogen synthase kinase 3 beta (GSK3b), which was found to be consistently expressed in primary GBM, also
declined. This suggests a functional link between Bmi1 and GSK3b. Interference with GSK3b activity by siRNA, the specific
inhibitor SB216763, or lithium chloride (LiCl) induced tumor cell differentiation. In addition, tumor cell apoptosis was
enhanced, the formation of neurospheres was impaired, and clonogenicity reduced in a dose-dependent manner. GBM cell
lines consist mainly of CD133-negative (CD133-) cells. Interestingly, ex vivo cells from primary tumor biopsies allowed the
identification of a CD133- subpopulation of cells that express stem cell markers and are depleted by inactivation of GSK3b.
Drugs that inhibit GSK3, including the psychiatric drug LiCl, may deplete the GBM stem cell reservoir independently of
CD133 status.
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Introduction
Recent studies suggest that cancer stem cells are the driving
force behind tumorigenesis [1]. CD133 (also known as Prominin 1)
was identified as a surface marker of cancer stem cells in brain
tumors [2]. As few as 100 CD133-positive (CD133+) cells were
shown to induce tumors in transplantation experiments giving rise
to a phenocopy of the initial neoplasia [2,3]. CD133+ cells, which
express multi-drug resistance and DNA repair proteins [4], are
highly resistant to chemo- and radiation therapy. However,
stemness is not restricted to the expression of the CD133 marker,
since CD133-negative (CD1332) cell populations were also found
to be tumorigenic [5]. Cancer stem cells have also been detected in
glioblastoma (GBM), the most malignant human brain tumor,
with an annual incidence of 36 per million and a mean survival of
less than 1 year [6–8]. GBM, a highly invasive and proliferative
tumor, manifests itself as a de novo lesion or progresses from less
undifferentiated low-grade astrocytoma.
Bmi1 is a member of the polycomb group of proteins involved
in brain development [9]. Polycomb group proteins maintain
embryonic and adult stem cells by forming multi-protein
complexes that function as transcription repressors [10–17].
Bmi1 is also involved in cancer by cooperation with Myc in
lymphoma formation [18] and blocking of senescence in
immortalized mouse embryonic fibroblasts through repression of
the Ink4a/Arf-locus [19]. It is also amplified and/or overexpressed
in non-small-cell lung cancer, colorectal carcinoma, nasopharyn-
geal carcinoma, medulloblastoma, lymphoma, multiple myeloma
and primary neuroblastoma [9,13,19–22]. Whether Bmi1 is
expressed in GBM is controversial [9]. In a mouse glioma model,
Bmi1 was implicated in tumorigenesis in an Ink4a/Arf-indepen-
dent manner [23]. Furthermore, it was shown recently that
microRNA-128 inhibits proliferation and self-renewal in glioma at
least partially by downregulating Bmi1 [24].
Glycogen synthase kinase 3 (GSK3), a serine/threonine kinase,
regulates numerous signaling pathways involved in cell cycle
control, proliferation, differentiation and apoptosis [25,26]. The
mammalian isoforms GSK3a and GSK3b are functionally
independent as GSK3a cannot rescue the embryonically lethal
phenotype of GSK3b (2/2) mice [27]. GSK3 has been described
as a pro-survival factor in pancreatic cancer [28] and as a pro-
apoptotic factor in colorectal cancer [29] and is interconnected with
several pathways and implicated in Alzheimer’s disease [30],
diabetes [31], bipolar disorder [32], and more recently cancer [33].
We have analyzed the role of GSK3 in malignant gliomas and
its links to critical signaling proteins. Downregulation of Bmi1
reduced GSK3b levels and induced the differentiation of
malignant glial cells. Direct inhibition of GSK3b by lithium
chloride (LiCl), SB216763 and siRNA decreased Nestin and Sox2
levels and induced the cell differentiation markers CNPase, glial
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and SB216763 depleted cancer stem cells grown as human GBM
ex vivo cell cultures, induced differentiation and inhibited neuro-
sphere formation. Thus, GSK3 may represent a novel therapeutic
target for malignant gliomas.
Materials and Methods
Patients
Tumor samples obtained from patients during a neurosurgical
procedure were immediately frozen and kept at 280uC. All patients
gave their written consent for the neurosurgical procedure and for
anonymous scientific analysis of diseased tissue according to the
guidelines of the Ethics Committee of Basel, Switzerland (EKBB).
Cell culture and reagents
LN319, LN18, LN215, U373, LN229, LN401, U343, U87,
BS125 and Hs683 glioma cell lines with defined genetic status of
TP53, p16/p14 and PTEN [34], DAOY medulloblastoma and
B104 neuroblastoma cell lines were cultured in Eagle medium
supplemented with 25 mM glucose, glutamine, standard antibiot-
ics, and 10% FCS. BS287 cells were cultured in Neurobasal
medium (Invitrogen) supplemented with basic fibroblast growth
factor (20 ng/ml, Invitrogen), epidermal growth factor (20 ng/ml,
R&D Systems), B27 (1x) and N2 supplement (0.5x) (Invitrogen).
All cells were maintained at 37uCi n5 %C O 2. The cell lines were
seeded in 6-cm plates at 5’000–10’000 cells/cm
2 and grown for
24 h prior to treatment. For cell counting, cells were treated for
72 h as described in the figure legends and counted by
hemocytometer. Lithium chloride (LiCl) was obtained from
MERCK and SB216763 from Tocris. Drug concentrations used
are indicated in the figure legends. LiCl was dissolved in PBS and
SB216763 in DMSO and stored at 220uC. The EGFR inhibitor
AEE788 was provided by Novartis Pharma. The c–secretase
inhibitor DAPT was obtained from Roche.
Colony formation assay
For each cell line, 500 cells were plated in triplicate into 94-mm
Petri dishes containing 10 ml of culture medium with 10% FCS.
Cells were grown for 14 days at 37uC and 5% CO2, during which
period the medium was not changed. Cells were then fixed with
4% formaldehyde in 1x PBS and stained with crystal violet.
BS287 ‘‘ex vivo’’ cell line formation and neurobasal
medium
Following informed consent, a tumor sample classified as GBM
based on the WHO criteria was obtained from a patient
undergoing surgical treatment at the University Hospital, Basel,
Switzerland. Within 1–3 h after surgical removal, the sample was
treated with the Neural Tissue Dissociation Kit (Miltenyi Biotec
GmbH) according to the manufacturer’s protocol. Tumor cells
were cultured in NBE media. Uncoated plastic dishes were used
for neurosphere culture of NBE cells.
Plasmids, lentiviruses and transfection
The lentiviral vectors pLKO.1-puro-scrambled-shRNA (Addgene)
and pLKO.1-puro-shRNA (Sigma, sh1061: CCGGCCTAATACTT-
TCCAGATTGATCTCGAGATCAATCTGG AAAGTATTAGGTTTTT,
sh693: CCGGCCAGACCACTACTGAATATAACTCGAGTTATA TTC-
AGTAGTGGTCTGGTTTT) targeting Bmi1 were transfected into
HEK293 cells together with plasmids encoding the packaging
(pCMV_dr8_91) and envelope proteins (pMD2-VSV-G) using
CaCl2 precipitation. The concentration of infectious particles in the
supernatant was titrated using HeLa cells. Glioma cells were
transduced with infectious viral particles. Stably transfected clones
were selected with 2 mg/ml puromycin. Bmi1 overexpression was
obtained with pBABE-puro and pBABE puro-Bmi1 using CaCl2
precipitation for 8 h. Stably transfected clones were selected with
2 mg/ml puromycin. siRNA transfection for GSK3 was performed
using the GSK-3a/b siRNA SignalSilence Kit (Cell Signaling
Technology) according to the manufacturer’s instructions. Cells were
transfected using the Amaxa Nucleofector device (Lonza). Cells
transfected with non-specific siRNA were used as a control.
Transwell migration assays
Transwell migration assays were performed using modified
Boyden chamber units with polycarbonate filters of 8-mm porosity
(Costar). The lower side of the filter was coated with 10 mg/ml
fibronectin for 2 h at 37uC. The bottom chamber was filled with
DMEM containing 10% FCS. Cells (10
4 per well in serum-free
DMEM) were plated in the upper chamber and incubated for 24 h
with or without GSK3b inhibitors. After removal of the remaining
cells from the upper surface of the filter, migrated cells at the
bottom of the filter were fixed with 3.7% formaldehyde in PBS
and stained with 0.1% crystal violet. For each treatment, cells in
10 fields of view were counted in three independent experiments.
Western blot analysis and antibodies
Cells were washed with 1x PBS, lysed in buffer containing 2%
sodium dodecyl sulfate (SDS), 50 mM Tris pH 6.8, 0.1 M dithiothre-
itol (DTT), boiled and used either immediately or frozen at 220uC.
Protein lysates were resolved on denaturing 8–12% SDS-polyacryl-
amide gels and transferred to nitrocellulose membranes (iBlot Gel
transfer stacks, Invitrogen). The following primary antibodies were
used: anti-Bmi1 (Upstate), anti-b-catenin and anti-Nestin (Santa Cruz
Biotechnology); anti-b-tubulin III and anti-GFAP (Sigma); anti-
CNPase (Chemicon); anti-GSK3b (Cell Signaling); anti-Notch2
(Developmental Studies Hybridoma Bank); anti-Sox2 (R&D systems);
anti-CD133 (Miltenyi Biotec); anti-Akt and phospho-Akt (Ser-473)
(Millipore, Billerica MA, USA), anti-p16/p14, anti-Bcl2, anti-Erk and
anti-phospho-Erk (Santa Cruz Biotechnology, Santa Cruz CA, USA),
anti-Actin (Sigma-Aldrich, St. Louis, USA). Decorated proteins were
revealed using horseradish peroxidase-conjugated anti-mouse, anti-
rabbit, anti-rat (New England Biolabs) or anti-goat (Pierce) secondary
antibodies and visualized by the chemoluminescence detection system
SuperSignal West Pico (Thermo Scientific). Protein bands were
quantified with ImageJ software (http://rsb.info.nih.gov/ij/). Results
were normalized to actin levels.
Cell sorting and flow cytometry
Cell DNA content and apoptosis were analyzed by flow
cytometry (CyAn ADP Analyzer, Beckman Coulter) and the
results statistically evaluated with Summit v4.3 software. Cells
were trypsinized, fixed in ice-cold 70% ethanol for 1 h and stained
with 50 mg/ml propidium iodide for FACS analysis. Percent dead
cells was determined from the proportion of cells in sub-G1 phase.
Results are given as mean values from three independent
experiments. For CD133 analysis, isolated cells were labeled with
anti-CD133 antibody (1:10) for 10 min at 4uC, washed with PBS
and sorted (INFLUX Cell Sorter by BD Biosciences).
For BrdU analysis, cells were pulsed with 10 mM bromodeoxy-
uridine for 2 h and processed with the APC-BrdU kit according to
the manufacturer’s instructions (BD Pharmingen). For fluorescent
labeling with GFAP, cells were fixed and permeabilized with the
Cytofix/Cytoperm kit (BD Pharmingen). Permeabilized cells were
incubated with anti-GFAP (1:200) or matching isotype control
antibody for 30 min on ice, washed twice and incubated with the
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by flow cytometry (CyAn ADP Analyzer, Beckman Coulter).
Immunocytochemistry
Cells were grown to 80% confluency as a monolayer as
described above. Cells were then fixed in 4% PFA in PBS for
15 min at room temperature, washed with PBS and incubated
with the primary antibody overnight at 4uC in PBS +1% BSA
+0.1% Triton X100. After thorough washing with PBS, the
secondary antibody was added for 3 h at room temperature. Cells
were imaged by confocal microscopy. All tumor samples analyzed
were stained with hematoxylin-eosin.
Microarray analysis of glioma
BS series are primary tumor tissues obtained from patients
diagnosed with primary CNS tumors classified according to the
WHO grading system. Normal brain tissue used as a template
for microarray was obtained from samples of brain surgery for
non-neoplastic disease. Total RNA from two normal brains, 12
GBM and eight astrocytoma samples was amplified and labeled
using the Affymetrix 2-cycle amplification protocol according to
the manufacturer’s instructions (Affymetrix). Samples were
hybridized to Affymetrix U133v2.0 GeneChips and scanned
using an Affymetrix Gene Chip scanner following the manu-
facturer’s instructions. Expression values were estimated using
the GC-RMA implementation in the Genedata Refiner 4.1
(Genedata, Basel, Switzerland) package. Data-mining and
visualization was performed using the Genedata Analyst 4.1
package. All samples were quantile normalized and median
scaled to correct for minor variation in expression distribution.
All microarray data reported in the manuscript are in
accordance with the MIAME guidelines.
Results
Bmi1 is overexpressed in GBM, oligodendroglioma and
astrocytoma
Bmi1 overexpression has been reported in several different
tumor types including medulloblastoma and neuroblastoma. In an
analysis of Bmi1 mRNA and protein expression in GBM cell lines
and primary brain tumors, all GBM cell lines expressed high Bmi1
levels, with the LN319 line having the highest expression
comparable to the reference line DAOY [9] (Figure 1A and data
not shown). In primary brain tumor samples, Bmi1 expression was
marked in 16/19 (84%) of GBM, 5/7 (71%) of oligodendroglioma
and 3/7 (42%) of astrocytoma. In contrast, fully differentiated
normal brain tissue had no Bmi1 protein (Figure 1B, C).
shRNAs against Bmi1 downregulates GSK3b
To study the role of Bmi1 in GBM, Bmi1 expression was
knocked down using lentiviral-mediated delivery of shRNAs. Bmi1
was efficiently downregulated in the Hs683, U373, U87, and
U343 GBM cell lines (Figures 2A and S1A and data not shown)
using different shRNA sequences (Figure S1B). Since the
Polycomb group gene Bmi1 is involved in the regulation of
development and tumorigenesis, the effect of Bmi1 downregula-
tion in GBM cells was screened by analysis of proteins involved in
key cellular pathways of the cell cycle, development, metabolism,
apoptosis and growth, including Erk, Akt, GSK3b, p16 and p14,
Bcl-2, c-Myc, Nestin and Sox2. In contrast to non-neoplastic cells
in Bmi1 knockout mice [19], Bmi1 downregulation in GBM cells
did not affect Ink4a/Arf protein levels (Figure 2A). Bmi1
downregulation induced cell differentiation associated with
morphological changes and decreased expression of the stem
cell-related proteins Nestin and Sox2, accompanying induction of
an astrocytic fate in U373 glioma cell line, determined by
increased levels of the astrocyte-specific marker GFAP, and
decreased levels of oligodendrocyte-specific marker CNPase
(Figures 2A–D and S2B). In contrast, Bmi1 overexpression
accompanied dedifferentiation as shown by increased Nestin
expression (Figure S1C). Interestingly, GSK3b levels were
markedly reduced (Figures 2A and S1A–B). This raised the
question of whether GSK3b mediates the effects observed on cell
differentiation. To this end, we used the small molecules LiCl and
SB216763 as well as siRNA to interfere with GSK3b activity in
GBM cells.
GSK3b is expressed in GBM
Thirty-two primary tumor tissues obtained from patients
diagnosed with GBM were studied using microarray and western
blot analysis to measure GSK3b mRNA and protein levels.
GSK3b mRNA were higher in GBM and astrocytoma patients
compared with the control (Figures 2E, F and S2) and protein was
found to be expressed in the majority of the tumors analyzed. The
high GSK3b expression in astrocytoma was most probably due to
greater necrosis in the GBM, with increased protein degradation
(Figure S2B).
siRNA- and drug-induced inhibition of GSK3 increases
differentiation markers
The effect of the inhibition of GSK3 on protein levels of
progenitor (Nestin and Sox2) and differentiation (CNPase, GFAP,
and b-tubulin III) markers in GBM cell lines U373, LN319, BS125
and LN18 was analyzed using the drugs LiCl and SB216763 or
siRNAs. b-catenin is targeted for degradation upon phosphoryla-
tion by GSK3b [25]. Blocking GSK3b therefore leads to
accumulation of b-catenin, which was used as a read-out for the
effects of LiCl and SB216763 on GSK3 activity (Figure 3B). After
72 h treatment with LiCl and SB216773, Nestin protein level
decreased in the Nestin-expressing U373, LN319 and LN18 cell
lines (Figures 3A, B), which was confirmed by immunocytochem-
istry (Figure 4B). Nestin and Sox2 were not expressed in the ‘‘ex
vivo’’ BS125 GBM cell line. Sox2 levels were reduced in LN18,
U373 and LN319 upon GSK3 inhibition (Figure 3A, B). The
oligodendrocyte specific marker 29,3 9-cyclic nucleotide 39-
phosphodiesterase (CNPase) and the neuronal marker b-tubulin
III increased in BS125, LN18 and LN319, (Figure 3A, B). GSK3
inhibition also increased the protein levels of the astrocytic lineage-
specific marker GFAP in LN319 and BS125 (Figure 4A).
Downregulation of GSK3 activity in LN18 by siRNA reduced
Nestin and Sox2 protein levels (Figure 4C), confirming the
specificity of the inhibitory drug SB216763 in blocking GSK3b.
The effect of the specific GSK3 inhibitor SB216763 was more
pronounced and consistent than the effect of LiCl, which is known
to target other signaling molecules [26]. Thus GSK3 inhibition
specifically decreased the expression of progenitor markers (Nestin
and Sox2) and induced the expression of differentiation markers
(neuronal marker b-tubulin III, oligodendrocyte-specific marker
CNPase and the astrocytic marker GFAP) in a cell line-dependent
manner.
Inhibition of GSK3 depletes GBM cells with a stem cell
signature
The phenotypic switch towards differentiation in GBM cells
following inhibition of GSK3 raises the question of whether GSK3
activity regulates cancer stem cell populations. CD133+ and CD1332
cancer stem cells have been described in GBM [2,3,35–37]. In an
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LN319, U373, LN229, U343, BS125 and Hs683) [34] for the presence
of CD133+ cells, only LN319 contained CD133+ cells, at approx-
imately 12%. To test whether the CD133+ population possessed a
cancer stem cell-like character, the expression levels of stem cell
markers were analyzed in the CD133-enriched population. Nestin,
Notch2 and Bmi1 were highly expressed relative to the CD1332
fraction (Figure 5C). GSK3b and b-catenin protein levels were also
higher in the CD133+ population than in the control (Figure 5C).
Inhibition of GSK3 in cell line LN319 with either LiCl or SB216763
showed a selective effect on the cancer stem cell-like population. LiCl at
10 mM and SB216763 at 20 mM induced a 50–60% depletion of
CD133+ cells (Figure 5A). The effects of GSK3 inhibitory drugs were
found to be specific in that the epidermal growth factor receptor
inhibitor (AEE788) and the c-secretase inhibitor (DAPT) did not
significantly alter the CD133+ population (data not shown). To further
consolidate this observation, we enriched the LN319 CD133+
population by FACS sorting, obtaining a CD133+ cell population of
approximately 80%. This was maintained for several passages and
then subjected to inhibition of GSK3 by LiCl or SB216763, which
depleted the CD133+ fraction (Figure 5B).
It has been argued that GBM cells grown for many passages in
standard medium do not mirror the stem cell compartment within
the original tumor [38]. To examine this, the ‘‘ex vivo’’ cell line
BS287 was analyzed which had been isolated from a fresh tumor
biopsy and directly grown as neurospheres in neurobasal medium
supplemented with bFGF and EGF, thus favoring expansion of
cancer stem cells. Interestingly, the population with a stem cell-like
signature in this cell line was represented by the CD133- and not
by the CD133+ population (Figure 6A–C). Only the CD1332
population expressed elevated levels of Nestin, Sox2 and Bmi1 and
formed neurospheres (Figure 6B, C). Inhibition of GSK3
decreased the stem cell like (CD1332) population (Figure 6D)
and also altered protein levels of stem cell and differentiation
markers, mainly decreased Sox2 levels (Figure S3). Induction of
differentiation impairs the ability of precursor cells to form
Figure 1. Bmi1 was highly expressed in GBM. Bmi1 expression in (A) GBM cell lines and (B) primary brain tumors. (C) Ratio of Bmi1-positive
primary tumors. NB: normal brain. EPEN: Ependymoma.
doi:10.1371/journal.pone.0007443.g001
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Bmi1 (sh1061) or with scrambled shRNA (scr). Bmi1 downregulation induced downregulation of the following proteins: p-AKT, Nestin (in U373), Bcl2,
and GSK3b. No effects are evident on the p16/p14
ARF, or p-ERK protein levels. (B) Scrambled control or U373 Bmi1-downregulated cells at
subconfluency (sub-con) or confluency (con). Bmi1-downregulated cells show differentiated morphology (arrow: long, branched processes). (C) The
glial fibrillary acidic protein (GFAP) levels in U373scr and U373sh1061 cells measured by flow cytometry. (D) Relative CNPase protein levels in U373scr
and U373sh1061 measured by western blotting, quantified using ImageJ software and normalized to b-actin levels. (E) GSK3b mRNA values from a
series of primary brain tumors (GBM and astrocytoma) and normal brain. (F) GSK3b protein is expressed in primary GBM. *P,0.05; one-way ANOVA
(Newman-Keuls Multiple Comparison Test).
doi:10.1371/journal.pone.0007443.g002
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7443Figure 3. GSK3 inhibitors specifically induced differentiation in GBM cell lines. Western blot analysis of Nestin, Sox2, CNPase, b -tubulin III
and b -actin (loading control) protein levels after treatment of GBM cell lines with GSK3 inhibitors (10 mM LiCl; 20 mM SB216763). Each cell line
showed a pro-differentiation response to GSK3b inhibitor application. (A) Protein bands quantified with ImageJ software. Protein levels were
normalized to b-actin for each cell line. (B) Corresponding western blots.
doi:10.1371/journal.pone.0007443.g003
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number and volume of neurospheres in BS287 cells (Figure 6E,
F). The results show that inhibition of GSK3 reduces the cancer
stem cell pool and that CD133 may not be a reliable cancer stem
cell marker.
GSK3 inhibition reduces colony formation and induces
apoptosis in GBM cells
The effects of GSK3 inhibition on cell proliferation and
apoptosis in the GBM cell lines LN18, U373, LN215 and
LN319 were analyzed using colony formation, relative cell number
and cell death as readout. In a colony formation assay, both the
number and size of colonies formed after 14 days of drug
treatment were measured. GSK3 inhibitors significantly reduced
colony formation in all GBM cell lines tested compared with the
untreated control (Figure 7A). The GSK3 inhibitor concentrations
used were in the non-toxic range; cell proliferation and survival of
the human adipose tissue-derived progenitor cells (A111) were not
negatively affected (Figure 7A). GSK3 inhibition by LiCl or
SB216763 induced a slight increase in cell death for GBM cell lines
LN319, LN18, U373 and BS125 after 72 h (Figure 7B). Induction
of cell death was significantly elevated when GSK3 inhibitor LiCl
was combined with the standard GBM therapeutic temozolomide
in the LN18 cell line (Figure 7D). Cell death was dose-dependent
and varied from cell line to cell line. Direct cell counting after
exposure of cells to LiCl or SB216763 for 72 h showed inhibition
of the proliferation of LN18, LN319, U373 and LN215 cells
(Figure 7C). G2-M accumulation was recorded in LN319, LN18,
U373 and G2-M arrest in LN215 (Figure S4). In a migration assay,
LN319 showed a significant reduction in cell migration following
GSK3 inhibition (Figure 7E). These results show that GSK3
strongly reduces colony formation and induces cell death in GBM
cell-lines.
Discussion
Bmi1, a member of the polycomb group proteins, is required for
self-renewal of neural stem cells and is upregulated in several
cancers. It is also known to repress Ink4a/Arf locus inhibiting
progenitor cell proliferation during neural differentiation [39]. In
differentiated cells, Bmi1 levels decrease while Ink4a/Arf protein
levels increase [40]. As the Ink4a/Arf locus is frequently deleted in
brain tumors [41], the role of Bmi1 overexpression in GBM cells
appears to be distinct from its repression of the Ink4a/Arf locus.
For example, downregulation of Bmi1 did not influence Ink4a/Arf
protein levels in tumor cells that retained the Ink4a/Arf locus.
Thus, in GBM cells, Bmi1 targets a different pathway. Screening
of several key proteins controlling cell cycle, development,
metabolism, apoptosis and growth, including Erk, Akt, GSK3b,
p16 and p14, Bcl-2, c-Myc, Nestin and Sox2, showed that
downregulation of Bmi1 reduced GSK3b protein levels and
induced differentiation in cancer cells. In addition, tumor cell
Figure 4. GSK3b downregulation by siRNA treatment induced differentiation. (A) The intensity of GFAP, an astrocyte-specific marker, was
measured by FACS analysis of GBM cell lines treated with 10 mM LiCl for 72 h. (B) Nestin immunostaining of cell lines U373 and LN18 after GSK3b
inhibition by LiCl (Li) or SB216763 (SB) for 72 h. (C) GSK3b siRNA reduced Sox2 and Nestin expression in the LN18 cell line. *P,0.05; one-way ANOVA
(Newman-Keuls Multiple Comparison Test). Scale bar in B is 30 mm.
doi:10.1371/journal.pone.0007443.g004
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reduced.
Discovered some 25 years ago [42], GSK3 has been considered
only recently as a therapeutic target for cancer [33]. It has been
shown that this enzyme negatively regulates the Wnt, Hedgehog
and Notch pathways, which are aberrantly activated in several
cancers [33,43]. This suggests that GSK3 inhibitors could exert a
therapeutically negative, pro-survival effect on tumor cells.
However, the long-term medical use of the GSK3 inhibitor LiCl
for the treatment of psychiatric disorders did not lead to an
increase in cancer incidence [44], arguing against an oncogenic
effect of GSK3 inhibitors. On the contrary, Cohen et al.
demonstrated that cancer prevalence in psychiatric patients on
long-term LiCl medication was lower than in the general
population [44], suggesting even a protective effect of LiCl. The
results presented here offer a molecular explanation of this
epidemiological observation: administration of LiCl induces
differentiation and inhibits proliferation and, thereby, might
effectively inhibit tumor formation and progression. Furthermore,
the plethora of clinical data on LiCl offer solid information about
potential side-effects and it appears safe to assume that normal
adult stem cells are not negatively affected, even by long-term use
of the drug. The very similar phenotypic and functional alterations
induced by either inhibiting GSK3 or by downregulating Bmi1 in
the present study points to a functional link between Bmi1 and
GSK3. However, further studies are needed to analyze whether
there is a direct interaction between Bmi1 and GSK3. Downreg-
ulating GSK3 specifically decreased the subpopulation of cancer
cells that contained a cancer stem cell-like signature by driving
them into differentiation.
Sox2 protein is widely expressed in the early neural plate and
early neural tube of several species [45]. In the developing
central nervous system, Sox2 expression becomes restricted to
the neuroepithelial cells of the ventricular layer, which continue
to divide and exhibit an immature phenotype. Cells that leave
the ventricular layer lose Sox2 expression [45]. Interestingly,
Sox2 has also been implicated in GBM [46,47] as downregu-
lation of Sox2 reduced cell proliferation and tumorigenicity in
GBM cells. Therefore, Sox2 was proposed as a new GBM
therapeutic target [46]. At present, inhibitors of Sox2 are not
available but the data presented here show that inhibition of
GSK3 strongly downregulates Sox2 in GBM cells. This raises
the possibility that LiCl or more specific GSK3-inhibitory drugs
could be used to decrease the Sox2-dependent tumorigenic
potential of GBM cells.
Two main strategies are currently being exploited to eradicate
the cancer stem cell (CSC) pool: i) chemotherapeutic regimens
that specifically drive CSC into apoptosis and thereby deplete
the CSC reservoir of the tumor, and ii) strategies aiming to drive
CSC into differentiation and thereby increase their susceptibility
to pro-apoptotic treatments [1]. Given the high degree of drug
resistance and the shared cellular and gene expression profiles of
adult and cancer stem cells [48], targeting CSC has proven to be
difficult. However, induction of differentiation remains a
therapeutic strategy for CSC as Piccirillo et al. showed that
bone morphogenetic proteins can induce differentiation of
CD133+ GBM cells, thereby reducing their tumorigenic
potential [49]. However, the use of morphogens bears the risk
of interfering with the tightly regulated adult stem cell niches.
Any strategy to induce differentiation in cancer stem cells must
be carefully assessed for any adverse effects on the adult stem cell
population.
Our results show GSK3 inhibition to be an attractive strategy
for specifically targeting a subpopulation of cancer cells with stem
Figure 5. GSK3b inhibition reduced the CD133+ cell population
of a GBM cell line. (A) LN319 GBM cell line was treated for 72 h with 10
or 20 mM LiCl or with SB216763 at 10 or 20 mM. GSK3b inhibition
reduced the CD133-positive (CD133+) population. (B) LN319 CD133+
cellswereenrichedto80%puritybycellsorting.Theenrichedpopulation
was treated for 72 h with 10 or 20 mM LiCl or with SB216763 at 10 or
20 mM. (C) Western blot analysis of Notch2, Nestin, Bmi1, b-catenin,
GSK3b and b-actin in CD133+ and CD133-negative (CD133-) enriched
populations compared with the control. **P,0.01; ***P,0.001; one-way
ANOVA (Newman-Keuls Multiple Comparison Test).
doi:10.1371/journal.pone.0007443.g005
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markers more accurately defined the subpopulation of cells within
GBM cell lines and ex vivo tumor cells than expression of the
CD133 marker. Inactivation of both Bmi1 and GSK3 depleted
precursor cells required for tumor maintenance and progression.
These data add another facet to the many effects of GSK3 as a
regulator of cancer cell identity. Here, GSK3 activation is
identified as a key element in maintaining stem cell-like
characteristics in a subset of cancer cells, providing these cells
with a higher self-renewal capacity. Recently, downregulation of
GSK3 was shown to induce apoptosis in glioma cells and to have
an anti-migratory effect in glioma sphreoids [50,51]. The role of
GSK3 inhibiton on differentiation was not analyzed. Optimal
therapies for cancer aim to spare normal cells with minimal or no
general toxicity while depleting malignant cells. The Wnt pathway
is involved in regulating cell processes as proliferation, apoptosis,
Figure 6. GSK3b inhibition reduced stem cell characteristics in an ‘‘ex vivo’’ GBM cell line. (A) CD133 sorting of the BS287 ‘‘ex vivo’’ GBM
cell line. (B) Growth characteristics of the CD133+ and CD133- populations in BS287. (C) Western blot analysis of Nestin, Sox2, Bmi1 and b-actin in
BS287. The CD133- population showed stem cancer-like characteristics. (D) Cells in the CD133+ population with a more differentiated geno/
phenotype increased after GSK3b inhibition. (E, F) Inhibition of GSK3b led to a reduction in the number and volume of neurospheres in the BS287
‘‘ex vivo’’ cell line.
doi:10.1371/journal.pone.0007443.g006
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described also as a major regulator of adult neurogenesis in the
hippocampus [52]. In the Wnt/b-catenin pathway GSK3b
mediates b-catenin degradation. Use of GSK3 inhibitors leads to
the accumulation of b-catenin, which then drives cells into
proliferation but this effect was not observed in the present study.
This may be explained by the constitutive activation of several
growth-promoting pathways, such as EGFR and PI3K, commonly
Figure 7. GSK3b inhibition reduced colony formation of GBM cells. (A) A colony formation assay was performed on GBM cell lines treated
with 10 mM LiCl or 20 mM SB216763 for 14 days. (B, C) GBM cell lines treated with LiCl or SB216763 for 72 h. (B) Percent cell death and (C) relative cell
number relative to the initial seeding. (D) Cell death determined by PI staining of the LN18 cell line after treatment with 10 mM LiCl with or without
50 mg/ml temozolomide (TMZ) for 72 h. *P,0.05, for the combination of LiCl and TMZ compared with each drug alone. (E) GSK3b inhibition
significantly reduced migration of the LN319 cell line. (B, C and E) Treated samples were compared to the corresponding control: *P,0.05; **P,0.01;
***P,0.001; one-way ANOVA (Newman-Keuls Multiple Comparison Test).
doi:10.1371/journal.pone.0007443.g007
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activation masking additional activation. Conversely, differentia-
tion- and apoptosis-inducing programs, which are low in cancer
cells, could be influenced by GSK3 inhibition and are, therefore,
directly detectable. On the opposite in normal system as in the
A111 cells GSK3 inhibition lead to an increased cell proliferation
in accordance with the previously described results in neural
progenitor cells [53].
shRNA against Bmi1 downregulated not only GSK3 but also
Bcl2, Nestin, Sox2 and not p16 and p14 (Figure 2A). The
microarray data showed higher levels of GSK3 expression in brain
tumors than in normal brain tissue, and protein was found to be
expressed in the majority of the tumors analyzed indicating a role
for GSK3 in GBM (Figure 2). GSK3 can thus be regarded as an
important regulator of tumor cell identity in GBM.
In conclusion, we propose GSK3 inhibitory drugs, e.g. LiCl, as
possible first- and/or second-line treatments complementing
standard cancer therapy.
The additive effect of combining the GSK3 inhibitor LiCl and
the standard GBM therapeutic temozolomide suggests possible
sensitization due to the induction of differentiation by interference
with GSK3 activity. In addition, the vast clinical experience of this
drug with psychiatric patients indicates safe application and the
lower cancer prevalence in LiCl-treated patients than in the
general population suggests a protective effect of the drug [44].
Clinically, LiCl could be tested in patients receiving standard
treatments in an additional therapeutic arm, the clinical hypothesis
being that long-term LiCl therapy in stabilized GBM patients may
delay tumor recurrence from the residual cancer stem cell pool by
driving cancer stem cells into differentiation and apoptosis.
Supporting Information
Figure S1 Bmi1 down-regulation reduces GSK3b protein levels.
(A) GBM cell line U87 is transduced with shRNA against Bmi1
(sh1061) or with scrambled shRNA (scr) (B) Bmi1 down regulation
lead to GSK3b reduction in Hs683 using a different shRNA
sequence. (C) Bmi1 down-regulation in U87 glioma cell line
decreased nestin protein levels, whereas Bmi1 over-expression
increased Nestin protein expression.
Found at: doi:10.1371/journal.pone.0007443.s001 (2.17 MB TIF)
Figure S2 GSK3b is expressed in primary brain tumors. (A)
GSK3b protein expression in a series of primary GBM (1–32). (B)
Photomicrograph of the immunohistochemical study showing
extensive necrotic areas in GBM compared to Astrocytoma
(Hematoxylin-Eosin staining). Arrows point to necrotic areas in
GBM.
Found at: doi:10.1371/journal.pone.0007443.s002 (3.18 MB TIF)
Figure S3 GSK3 inhibition induces differentiation of the BS287
‘‘ex vivo’’ cell line. Nestin, Sox2, b-catenin, CNPase, b-tubulin III
and b-actin protein expression upon GSK3 inhibition (with LiCl
and SB216763 for either 24 or 72 hours) on the BS287 ‘‘ex vivo’’
cell line.
Found at: doi:10.1371/journal.pone.0007443.s003 (1.82 MB TIF)
Figure S4 Cell cycle analysis in GBM cell lines treated with
LiCl. The GBM cell lines LN319, LN18, U373 and LN215 were
treated with 10 or 20 mM LiCl for 24 hours. Percentage of the
cells in G1, S and G2-M phase of the cell cycle were evaluated by
FACS analysis.
Found at: doi:10.1371/journal.pone.0007443.s004 (2.11 MB TIF)
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